The Philadelphia-based biotech firm added the executive to support the scaling of its drug discovery platform.
Live Poll
Do you trust that new corporate board appointments improve a biotech company's focus on patient needs?
September 28, 2026
Philadelphia Startup Licensed Anti-IL-33 Drug for TrialsTolerance Bio acquired the asset from Tanabe Pharma to restore thymic function and improve immune resilience.
September 23, 2026
Philadelphia Hosted Record Pharma ConferenceThe 2026 Fierce Pharma Week drew 3,500 industry leaders to Philadelphia, marking a 21% increase in overall event attendance.
September 19, 2026
Latus Bio Appointed New Board LeadersThe Philadelphia-based developer of gene therapies has added pharmaceutical and financial expertise to its board.
